Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II MK-0457 in BCR-ABL T315I mutant CML and Philadelphia chromosome-positive acute lymphoblastic leukemia
2006-004535-30Phase 2Terminated
- Sponsor
- Merck & Co.
- Start
- Jan 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tozasertib in chronic myelogenous leukemia (CML) and acute lymphoblastic leukemia (ALL), sponsored by Merck & Co. Primary endpoints: Major cytogenetic response and Major hematological response. Started Jan 2007; status: terminated.
02
Drugs
tozasertib
03
Conditions
chronic myelogenous leukemia (CML)acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on 2006-004535-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-004535-30.